UK's BBI joins Inverness growing family
This article was originally published in Clinica
Inverness Medical Innovations has completed the acquisition of Cardiff, Wales-based diagnostics company BBI. Inverness paid at total of £63.2m ($123.2m) in cash and around 251,300 shares of its common stock for the UK developer of noninvasive lateral flow tests and gold reagents. In December 2007, BBI became one in a string of acquisitions made by Inverness throughout the year (see Clinica No 1286, p 3).
You may also be interested in...
A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilico’s machine learning technology in target validation.
The introduction of gene therapies has been the highest-profile new modality to reach the market, but new RNA-based therapeutics hold significant potential and could be more accessible for patients. Scrip reviews the leading drug developers in this space.